KratomNC – Warning Letter

On May 16, 2019, the U.S. Food and Drug Administration (FDA) issued a Warning Letter to KratomNC, highlighting significant concerns regarding the marketing and safety of its kratom products. The FDA emphasized that KratomNC had made misleading health claims about the efficacy of kratom in treating various medical conditions, which have not been substantiated by scientific evidence. Additionally, the letter outlined safety concerns associated with kratom consumption, including risks of addiction, adverse health effects, and potential contamination of products. The FDA indicated that KratomNC’s practices violated regulatory standards, specifically in terms of product labeling and manufacturing guidelines. The letter concluded by requiring a response from the company within a specified time frame, detailing the measures it would take to rectify these issues and ensure compliance with federal regulations. This warning underscores the ongoing scrutiny of kratom products in the U.S. market and the importance of adhering to safety and marketing regulations.

For further reading:

https://kri.org/wp-content/uploads/2024/10/KratomNC-Warning-Letter-05_16_2019.pdf

More Posts